Clinical trial
Patient Self-Administered Intralesional Injections of Triamcinolone for Acne Vulgaris
NCT06186596 is registered in ClinicalTrials.gov with ACOM Labs as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Patient Self-Administered Intralesional Injections of Triamcinolone for Acne Vulgaris
- Lead sponsor
- ACOM Labs
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- February 1, 2023
- Completion date
- January 31, 2024
- Enrollment
- 150 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.